Fed Circuit affirms GSK $107m patent loss
20-11-2020
Sandoz secures victory against GSK in passing off case
08-10-2019
GSK ordered to pay Vectura $89.7m in patent damages
07-05-2019
Willy Barton / Shutterstock.com
A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline (GSK) has willfully infringed one of its patents.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
GlaxosmithKline, Vectura, US District Court for the District of Delaware, patent infringement, Ellipta
